Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.2283
- Book/Share 15.6573
- PB 1.5854
- Debt/Equity 0.6967
- CurrentRatio 1.1584
- ROIC 0.1119
- MktCap 140632079250.0
- FreeCF/Share 2.1879
- PFCF 11.3066
- PE 13.1076
- Debt/Assets 0.2998
- DivYield 0.0691
- ROE 0.1194
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Prediction: These Could Be the Best-Performing Value Stocks Through 2030
Published: February 23, 2025 by: The Motley Fool
Sentiment: Positive
Buying quality stocks when they're unpopular can be very rewarding.
Read More
2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
Published: February 21, 2025 by: The Motley Fool
Sentiment: Positive
Looking for a good area in which to invest? Consider the healthcare sector.
Read More
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
Published: February 20, 2025 by: Seeking Alpha
Sentiment: Positive
The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annualized dividend income. I added to positions in Pfizer, Starwood Property Trust, and Reaves Utility Income Trust, focusing on undervalued stocks with strong dividend yields.
Read More
The Smartest Dividend Stocks to Buy With $1,000 Right Now
Published: February 20, 2025 by: The Motley Fool
Sentiment: Positive
You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Might I suggest some dividend payers?
Read More
Pfizer Stock's Upside Got Bigger
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Stock's Upside Got Bigger
Read More
Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.
Published: February 18, 2025 by: CNBC Television
Sentiment: Positive
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.
Read More
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.
Read More
Sticky Inflation Won't Go Away: 4 High-Yield Dividend Stocks That Always Work
Published: February 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
While the recent inflation data is undoubtedly far better than the 9.1% increase printed in the summer of 2022, many Americans still face the reality that prices for everyday necessities like food, energy, and other necessities remain very elevated.
Read More
3 Things You Need to Know If You Buy Pfizer Today
Published: February 18, 2025 by: The Motley Fool
Sentiment: Positive
Pfizer (PFE -0.43%) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent times. Thanks to its coronavirus treatment and vaccine, the pharma giant reported more than $100 billion in revenue in 2022 at the peak of its pandemic success.
Read More
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
Published: February 17, 2025 by: The Motley Fool
Sentiment: Positive
Buy low, sell high. That has been a good strategy for investors for a long time.
Read More
Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell
Published: February 17, 2025 by: Seeking Alpha
Sentiment: Positive
I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 billion from 2025 revenue, with PFE now responsible for 20% of catastrophic drug costs. Danuglipron could be Pfizer's turnaround catalyst if late stage trials succeed in 2025. I expect its potential launch in late 2026 or early 2027 to boost investor sentiment.
Read More
3 Brand-Name, Ultra-High-Yield Dividend Stocks Patient Investors Can Confidently Buy With $300 Right Now
Published: February 13, 2025 by: The Motley Fool
Sentiment: Positive
With thousands of publicly traded companies and exchange-traded funds (ETFs) to choose from, Wall Street offers no shortage of ways for investors to grow their wealth. But among this vast sea of pathways to become richer is one of the most-successful strategies: buying and holding high-quality dividend stocks.
Read More
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothel.
Read More
A Historic Opportunity To Win Big With Dividend Stocks
Published: February 10, 2025 by: Seeking Alpha
Sentiment: Positive
The current market offers a historic opportunity for dividend stocks. We detail why this is a historic opportunity for dividend investors. We also discuss some of the names that we are buying to take advantage of this opportunity.
Read More
Better High-Yield Dividend Stock: Pfizer vs. Merck
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of Merck (MRK -0.88%) that offer a yield above 3%, and shares of Pfizer (PFE -0.35%) offer a yield above 6%.
Read More
3 No-Brainer Healthcare Stocks to Buy With $200 Right Now
Published: February 10, 2025 by: The Motley Fool
Sentiment: Positive
Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative biotech that may launch game-changing products down the road.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000